Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
DNLI
DNLI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DNLI News
Denali Sells Rare Pediatric Disease Priority Review Voucher for $195 Million
17h ago
NASDAQ.COM
Denali Therapeutics Sells Priority Review Voucher for $195M
1d ago
seekingalpha
Denali Sells Rare Pediatric Disease Priority Review Voucher for $195 Million
1d ago
NASDAQ.COM
US Stocks Close Higher as Market Sentiment Improves
May 22 2026
NASDAQ.COM
US Stocks Rise, Nasdaq Hits Weekly High
May 22 2026
NASDAQ.COM
US Stocks Rise as Market Optimism Grows
May 22 2026
NASDAQ.COM
Biogen and Denali Halt Development of Parkinson's Drug BIIB122
May 22 2026
seekingalpha
Biogen and Denali Halt Development of Parkinson's Drug BIIB122
May 22 2026
NASDAQ.COM
Biogen and Denali Halt Parkinson's Drug Development
May 21 2026
stocktwits
Biogen and Denali Discontinue BIIB122 Development in Parkinson's Disease
May 21 2026
Globenewswire
Biogen and Denali Discontinue BIIB122 Development in Parkinson's Disease
May 21 2026
Newsfilter
ADAR1 Capital Management Increases Stake in Denali Therapeutics
May 18 2026
Fool
Denali Therapeutics Q1 Financial Results Analysis
May 07 2026
seekingalpha
Privium Fund Management Acquires Stake in Denali Therapeutics
May 05 2026
Fool
Transformation of Value in Biotechnology Sector
Apr 20 2026
Globenewswire
Biotechnology Sector Undergoes Value Transformation
Apr 20 2026
Newsfilter
Show More News
